Combined hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b vaccine; Infanrix™ hexa

References

• Marshall GS, Happe LE, Lunacsek OE, Szymanski MD, Woods CR, Zahn M, Russell A. Use of combination vaccines is associated with improved coverage rates. Pediatr Infect Dis J 2007; 26:496 - 500; http://dx.doi.org/10.1097/INF.0b013e31805d7f17; PMID: 17529866
   PubMed Web of Science ®Google Scholar
• Happe LE, Lunacsek OE, Kruzikas DT, Marshall GS. Impact of a pentavalent combination vaccine on immunization timeliness in a state Medicaid population. Pediatr Infect Dis J 2009; 28:98 - 101; http://dx.doi.org/10.1097/INF.0b013e318187d047; PMID: 19148039
   PubMed Web of Science ®Google Scholar
• Happe LE, Lunacsek OE, Marshall GS, Lewis T, Spencer S. Combination vaccine use and vaccination quality in a managed care population. Am J Manag Care 2007; 13:506 - 12; PMID: 17803364
   PubMed Web of Science ®Google Scholar
• Kalies H, Grote V, Verstraeten T, Hessel L, Schmitt H-J, von Kries R. The use of combination vaccines has improved timeliness of vaccination in children. Pediatr Infect Dis J 2006; 25:507 - 12; http://dx.doi.org/10.1097/01.inf.0000222413.47344.23; PMID: 16732148
   PubMed Web of Science ®Google Scholar
• Infanrix hexa product information. 2011 Sep 14 [cited 2013 Feb 18]; Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000296/human_med_000833.jsp&mid=WC0b01ac058001d124
   Google Scholar
• Poolman JT, Hallander HO. Acellular pertussis vaccines and the role of pertactin and fimbriae. Expert Rev Vaccines 2007; 6:47 - 56; http://dx.doi.org/10.1586/14760584.6.1.47; PMID: 17280478
   PubMed Web of Science ®Google Scholar
• Bassinet L, Gueirard P, Maitre B, Housset B, Gounon P, Guiso N. Role of adhesins and toxins in invasion of human tracheal epithelial cells by Bordetella pertussis.. Infect Immun 2000; 68:1934 - 41; http://dx.doi.org/10.1128/IAI.68.4.1934-1941.2000; PMID: 10722585
   PubMed Web of Science ®Google Scholar
• Zepp F, Schmitt H-J, Cleerbout J, Verstraeten T, Schuerman L, Jacquet J-M. Review of 8 years of experience with Infanrix hexa (DTPa-HBV-IPV/Hib hexavalent vaccine). Expert Rev Vaccines 2009; 8:663 - 78; http://dx.doi.org/10.1586/erv.09.32; PMID: 19485747
   PubMed Web of Science ®Google Scholar
• Carlsson RM, Claesson BA, Selstam U, Fagerlund E, Granström M, Blondeau C, Hoffenbach A. Safety and immunogenicity of a combined diphtheria-tetanus-acellular pertussis-inactivated polio vaccine-Haemophilus influenzae type b vaccine administered at 2-4-6-13 or 3-5-12 months of age. Pediatr Infect Dis J 1998; 17:1026 - 33; http://dx.doi.org/10.1097/00006454-199811000-00013; PMID: 9849987
   PubMed Web of Science ®Google Scholar
• Taranger J, Trollfors B, Knutsson N, Sundh V, Lagergård T, Ostergaard E. Vaccination of infants with a four-dose and a three-dose vaccination schedule. Vaccine 1999; 18:884 - 91; http://dx.doi.org/10.1016/S0264-410X(99)00341-2; PMID: 10580202
   PubMed Web of Science ®Google Scholar
• Marino MG, Franco E. [Immunization in the 3rd, 5th and 11th month of age: an Italian intuition]. Ig Sanita Pubbl 2008; 64:391 - 401; PMID: 18936801
   PubMedGoogle Scholar
• Sintesi anni 2000-2011 - Ministero della Salute. Vaccinazioni dell’età pediatrica: coperture vaccinali* (per 100 abitanti) in Italia. 2012. Available from: http://www.salute.gov.it/imgs/C_17_pagineAree_811_listaFile_itemName_11_file.pdf
   Google Scholar
• Avdicová M, Prikazský V, Hudecková H, Schuerman L, Willems P. Immunogenicity and reactogenicity of a novel hexavalent DTPa-HBV-IPV/Hib vaccine compared to separate concomitant injections of DTPa-IPV/Hib and HBV vaccines, when administered according to a 3, 5 and 11 month vaccination schedule. Eur J Pediatr 2002; 161:581 - 7; http://dx.doi.org/10.1007/s00431-002-1079-5; PMID: 12424582
   PubMed Web of Science ®Google Scholar
• Avdicová M, Crasta PD, Hardt K, Kovac M. Lasting immune memory against hepatitis B 10 years after the 2+1 primary vaccination schedule with DTPa-HBV-IPV/Hib or DTPa-IPV/Hib+HBV. 30th annual meeting of the European Society for Paediatric Infectious Diseases (ESPID). Thessalonika, Greece: 2012.
   Google Scholar
• Van Der Meeren O, Kuriyakose S, Kolhe D, Hardt K. Immunogenicity of Infanrix™ hexa administered at 3, 5 and 11 months of age. Vaccine 2012; 30:2710 - 4; http://dx.doi.org/10.1016/j.vaccine.2012.02.024; PMID: 22349525
   PubMed Web of Science ®Google Scholar
• Gabutti G, Zepp F, Schuerman L, Dentico P, Bamfi F, Soncini R, Habermehl P, Knuf M, Crovari P, Cooperative Italian Group for the Study of Combined Vaccines. Evaluation of the immunogenicity and reactogenicity of a DTPa-HBV-IPV Combination vaccine co-administered with a Hib conjugate vaccine either as a single injection of a hexavalent combination or as two separate injections at 3, 5 and 11 months of age. Scand J Infect Dis 2004; 36:585 - 92; http://dx.doi.org/10.1080/00365540410017572; PMID: 15370670
   PubMed Web of Science ®Google Scholar
• Kilpi TM, Silfverdal SA, Nilsson L, Syrjänen R, Belloni C, Desole M, Triban C, Storsaeter J, Soila M, Jacquet JM. Immunogenicity and reactogenicity of two diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio virus-Haemophilus influenzae type b vaccines administered at 3, 5 and 11-12 months of age. Hum Vaccin 2009; 5:18 - 25; http://dx.doi.org/10.4161/hv.5.1.6369; PMID: 18690013
   PubMed Web of Science ®Google Scholar
• Vesikari T, Forstén A, Desole MG, Ferrera G, Caubet M, Mesaros N, Boutriau D. A combined Haemophilus influenzae type B Neisseria meningitidis serogroup C tetanus toxoid conjugate vaccine is immunogenic and well-tolerated when coadministered with diphtheria, tetanus, acellular pertussis hepatitis B-inactivated poliovirus at 3, 5 and 11 months of age: results of an open, randomized, controlled study. Pediatr Infect Dis J 2013; 32:521 - 9; http://dx.doi.org/10.1097/INF.0b013e31827e22e3; PMID: 23190785
   PubMed Web of Science ®Google Scholar
• Esposito S, Tansey S, Thompson A, Razmpour A, Liang J, Jones TR, Ferrera G, Maida A, Bona G, Sabatini C, et al. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers. Clin Vaccine Immunol 2010; 17:1017 - 26; http://dx.doi.org/10.1128/CVI.00062-10; PMID: 20427630
   PubMed Web of Science ®Google Scholar
• Durando P, Crovari P, Ansaldi F, Sticchi L, Sticchi C, Turello V, Marensi L, Giacchino R, Timitilli A, Carloni R, et al, Collaborative Group for Pneumococcal Vaccination in Liguria. Universal childhood immunisation against Streptococcus pneumoniae: the five-year experience of Liguria Region, Italy. Vaccine 2009; 27:3459 - 62; http://dx.doi.org/10.1016/j.vaccine.2009.01.052; PMID: 19200823
   PubMed Web of Science ®Google Scholar
• Melville-Smith ME, Seagroatt VA, Watkins JT. A comparison of enzyme-linked immunosorbent assay (ELISA) with the toxin neutralization test in mice as a method for the estimation of tetanus antitoxin in human sera. J Biol Stand 1983; 11:137 - 44; http://dx.doi.org/10.1016/S0092-1157(83)80038-9; PMID: 6345548
   PubMedGoogle Scholar
• Camargo ME, Silveira L, Furuta JA, Oliveira EP, Germek OA. Immunoenzymatic assay of anti-diphtheric toxin antibodies in human serum. J Clin Microbiol 1984; 20:772 - 4; PMID: 6386879
   PubMed Web of Science ®Google Scholar
• Granström M, Thorén M, Blennow M, Tiru M, Sato Y. Acellular pertussis vaccine in adults: adverse reactions and immune response. Eur J Clin Microbiol 1987; 6:18 - 21; http://dx.doi.org/10.1007/BF02097184; PMID: 2883004
   PubMedGoogle Scholar
• Karpinski KF, Hayward S, Tryphonas H. Statistical considerations in the quantitation of serum immunoglobulin levels using the enzyme-linked immunosorbent assay (ELISA). J Immunol Methods 1987; 103:189 - 94; http://dx.doi.org/10.1016/0022-1759(87)90289-4; PMID: 3668258
   PubMed Web of Science ®Google Scholar
• Schmitt HJ, Schuind A, Knuf M, Beutel K, Schulte-Wissermann H, Gahr M, Schult R, Folkens J, Rauh W, Bogaerts H, et al. Clinical experience of a tricomponent acellular pertussis vaccine combined with diphtheria and tetanus toxoids for primary vaccination in 22,505 infants. J Pediatr 1996; 129:695 - 701; http://dx.doi.org/10.1016/S0022-3476(96)70152-X; PMID: 8917236
   PubMed Web of Science ®Google Scholar
• Schmitt HJ, von König CH, Neiss A, Bogaerts H, Bock HL, Schulte-Wissermann H, Gahr M, Schult R, Folkens JU, Rauh W, et al. Efficacy of acellular pertussis vaccine in early childhood after household exposure. JAMA 1996; 275:37 - 41; http://dx.doi.org/10.1001/jama.1996.03530250041024; PMID: 8531284
   PubMed Web of Science ®Google Scholar
• Greco D, Salmaso S, Mastrantonio P, Giuliano M, Tozzi AE, Anemona A, Ciofi degli Atti ML, Giammanco A, Panei P, Blackwelder WC, et al, Progetto Pertosse Working Group. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. N Engl J Med 1996; 334:341 - 8; http://dx.doi.org/10.1056/NEJM199602083340601; PMID: 8538704
   PubMed Web of Science ®Google Scholar
• Salmaso S, Mastrantonio P, Tozzi AE, Stefanelli P, Anemona A, Ciofi degli Atti ML, Giammanco A, Stage III Working Group. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience. Pediatrics 2001; 108:E81; http://dx.doi.org/10.1542/peds.108.5.e81; PMID: 11694665
   PubMed Web of Science ®Google Scholar
• Hallander HO, Gustafsson L. Efficacy and effectiveness of acellular pertussis vaccines: a 20-year Swedish experience. Expert Rev Vaccines 2009; 8:1303 - 7; http://dx.doi.org/10.1586/erv.09.88; PMID: 19803750
   PubMed Web of Science ®Google Scholar
• Nilsson L, Lepp T, von Segebaden K, Hallander H, Gustafsson L. Pertussis vaccination in infancy lowers the incidence of pertussis disease and the rate of hospitalisation after one and two doses: analyses of 10 years of pertussis surveillance. Vaccine 2012; 30:3239 - 47; http://dx.doi.org/10.1016/j.vaccine.2011.10.089; PMID: 22094282
   PubMed Web of Science ®Google Scholar
• Gabutti G, Rota MC, Bonato B, Pirani R, Turlà G, Cucchi A, Cavallaro A. Hospitalizations for pertussis in Italy, 1999-2009: analysis of the hospital discharge database. Eur J Pediatr 2012; 171:1651 - 5; http://dx.doi.org/10.1007/s00431-012-1791-8; PMID: 22790868
   PubMed Web of Science ®Google Scholar
• Forsyth KD, Wirsing von Konig C-H, Tan T, Caro J, Plotkin S. Prevention of pertussis: recommendations derived from the second Global Pertussis Initiative roundtable meeting. Vaccine 2007; 25:2634 - 42; http://dx.doi.org/10.1016/j.vaccine.2006.12.017; PMID: 17280745
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant women--Advisory Committee on Immunization Practices (ACIP), 2012. MMWR Morb Mortal Wkly Rep 2013; 62:131 - 5; PMID: 23425962
   PubMed Web of Science ®Google Scholar
• Simonetti A, Martini I, Bonomo G, D’Avino R, Puggina P, Vairo U, Piscopo P, Marchetti F. Improving adherence rates to a cocooning program: A pilot experience in Italy. Hum Vaccin Immunother 2013; 9; Forthcoming http://dx.doi.org/10.4161/hv.23795; PMID: 23370334
   PubMedGoogle Scholar
• Prato R, Martinelli D, Marchetti F, Fortunato F, Tafuri S, Germinario CA. Feasibility of a cocoon strategy for the prevention of pertussis in Italy: a survey of prevention department healthcare providers. Pediatr Infect Dis J 2012; 31:1304 - 7; http://dx.doi.org/10.1097/INF.0b013e31826b7110; PMID: 22863911
   PubMed Web of Science ®Google Scholar
• Misegades LK, Winter K, Harriman K, Talarico J, Messonnier NE, Clark TA, Martin SW. Association of childhood pertussis with receipt of 5 doses of pertussis vaccine by time since last vaccine dose, California, 2010. JAMA 2012; 308:2126 - 32; http://dx.doi.org/10.1001/jama.2012.14939; PMID: 23188029
   PubMed Web of Science ®Google Scholar
• Klein NP, Bartlett J, Rowhani-Rahbar A, Fireman B, Baxter R. Waning protection after fifth dose of acellular pertussis vaccine in children. N Engl J Med 2012; 367:1012 - 9; http://dx.doi.org/10.1056/NEJMoa1200850; PMID: 22970945
   PubMed Web of Science ®Google Scholar
• Tartof SY, Lewis M, Kenyon C, White K, Osborn A, Liko J, Zell E, Martin S, Messonnier NE, Clark TA, et al. Waning immunity to pertussis following 5 doses of DTaP. Pediatrics 2013; 131:e1047 - 52; http://dx.doi.org/10.1542/peds.2012-1928; PMID: 23478868
   PubMed Web of Science ®Google Scholar
• Quinn HE, McIntyre P. Pertussis vaccine effectiveness in Australia. 2011 [cited 21 June 2013]. Available from: http://www.ncirs.edu.au/news/past-news-events/Day%201/HQuinn-Australia-PertussisWS-25_26Aug11.pdf
   Google Scholar
• Booy R, Van der Meeren O, Ng S-P, Celzo F, Ramakrishnan G, Jacquet J-M. A decennial booster dose of reduced antigen content diphtheria, tetanus, acellular pertussis vaccine (Boostrix™) is immunogenic and well tolerated in adults. Vaccine 2010; 29:45 - 50; http://dx.doi.org/10.1016/j.vaccine.2010.10.025; PMID: 20974302
   PubMed Web of Science ®Google Scholar
• Mertsola J, Van Der Meeren O, He Q, Linko-Parvinen A, Ramakrishnan G, Mannermaa L, Soila M, Pulkkinen M, Jacquet JM. Decennial administration of a reduced antigen content diphtheria and tetanus toxoids and acellular pertussis vaccine in young adults. Clin Infect Dis 2010; 51:656 - 62; http://dx.doi.org/10.1086/655825; PMID: 20704493
   PubMed Web of Science ®Google Scholar
• Poovorawan Y, Chongsrisawat V, Theamboonlers A, Leroux-Roels G, Kuriyakose S, Leyssen M, Jacquet JM. Evidence of protection against clinical and chronic hepatitis B infection 20 years after infant vaccination in a high endemicity region. J Viral Hepat 2011; 18:369 - 75; http://dx.doi.org/10.1111/j.1365-2893.2010.01312.x; PMID: 20384962
   PubMed Web of Science ®Google Scholar
• Poovorawan Y, Chongsrisawat V, Theamboonlers A, Bock HL, Leyssen M, Jacquet J-M. Persistence of antibodies and immune memory to hepatitis B vaccine 20 years after infant vaccination in Thailand. Vaccine 2010; 28:730 - 6; http://dx.doi.org/10.1016/j.vaccine.2009.10.074; PMID: 19892043
   PubMed Web of Science ®Google Scholar
• Mast E, Mahoney F, Kane M, Margolis H. Hepatitis B Vaccine In: PLotkin SA, Orenstein WA, eds. Vaccines. 4th edition. Philadelphia: Saunders Elsevier; 2004. p. 299–337.
   Google Scholar
• Zinke M, Kappes R, Kindler K, Paulus-Koschik A, Goering U, Disselhoff J, Soemantri P, Grunert D, Laakmann KH, Gunasekaran R, et al. Immune memory to hepatitis B virus in 4-9-year old children vaccinated in infancy with four doses of hexavalent DTPa-HBV-IPV/Hib vaccine. Hum Vaccin 2009; 5:592 - 8; PMID: 19535920
   PubMed Web of Science ®Google Scholar
• Heininger U, Sänger R, Jacquet J-M, Schuerman L, DTP-HBV-IPV-059 Study Group, DTP-HBV-IPV-096 Study Group. Booster immunization with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate combination vaccine in the second year of life: safety, immunogenicity and persistence of antibody responses. Vaccine 2007; 25:1055 - 63; http://dx.doi.org/10.1016/j.vaccine.2006.09.060; PMID: 17049692
   PubMed Web of Science ®Google Scholar
• Steiner M, Ramakrishnan G, Gartner B, Van Der Meeren O, Jacquet J-M, Schuster V. Lasting immune memory against hepatitis B in children after primary immunization with 4 doses of DTPa-HBV-IPV/Hib in the first and 2nd year of life. BMC Infect Dis 2010; 10:9; http://dx.doi.org/10.1186/1471-2334-10-9; PMID: 20078876
   PubMed Web of Science ®Google Scholar
• Giambi C, Bella A, Barale A, Montù D, Marchisio M, Oddone M, Zito S, Rapicetta M, Chionne P, Madonna E, et al. A cohort study to evaluate persistence of hepatitis B immunogenicity after administration of hexavalent vaccines. BMC Infect Dis 2008; 8:100; http://dx.doi.org/10.1186/1471-2334-8-100; PMID: 18662386
   PubMed Web of Science ®Google Scholar
• Zanetti AR, Romanò L, Giambi C, Pavan A, Carnelli V, Baitelli G, Malchiodi G, Valerio E, Barale A, Marchisio MA, et al, study group. Hepatitis B immune memory in children primed with hexavalent vaccines and given monovalent booster vaccines: an open-label, randomised, controlled, multicentre study. Lancet Infect Dis 2010; 10:755 - 61; http://dx.doi.org/10.1016/S1473-3099(10)70195-X; PMID: 20884297
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Questions and answers on the suspension of Hexavac. Doc. Ref. EMEA/304888/200. 2005 Sep 20 [cited 2013 Feb 19];Available from: http://www.emea.europa.eu/docs/en_GB/document_library/Medicine_QA/2009/12/WC500017700.pdf
   Google Scholar
• European Medicines Agency. Summary of Opinion. Hexaxim. EMA/CHMP/409930/2012. 2012 Jun [cited 2013 July 31]; Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Other/2012/06/WC500129095.pdf
   Google Scholar
• WHO Expanded Programme on Immunization. Guidelines for WHO/EPI collaborative studies on poliomyelitis: standard procedure for determining immunity to poliovirus using the microneutralization test. Geneva: World Health Organization. 1993. Available from: http://www.who.int/iris/handle/10665/70486#sthash.dQOk5dbw.dpuf
   Google Scholar
• Tichmann I, Preidel H, Grunert D, Habash S, Schult R, Maier R, Gildberg PK, Sengespeik HC, Meurice F, Sänger R. Comparison of the immunogenicity and reactogenicity of two commercially available hexavalent vaccines administered as a primary vaccination course at 2, 4 and 6 months of age. Vaccine 2005; 23:3272 - 9; http://dx.doi.org/10.1016/j.vaccine.2005.01.087; PMID: 15837232
   PubMed Web of Science ®Google Scholar
• Giambi C, Bella A, Barale A, Montù D, Marchisio M, Oddone M, Zito S, Rapicetta M, Chionne P, Madonna E, et al. A cohort study to evaluate persistence of hepatitis B immunogenicity after administration of hexavalent vaccines. BMC Infect Dis 2008; 8:100; http://dx.doi.org/10.1186/1471-2334-8-100; PMID: 18662386
   PubMed Web of Science ®Google Scholar
• Certification of the Region’s polio-free status in 2002. [cited 2013 Feb 19];Available from: http://www.euro.who.int/en/what-we-do/health-topics/communicable-diseases/poliomyelitis/activities/polio-certification-activities/certification-of-the-regions-polio-free-status-in-2002
   Google Scholar
• Baldo V, Baldovin T, Cocchio S, Lazzari R, Saracino E, Bertoncello C, Buja A, Trevisan A. Seroepidemiology of polioviruses among university students in northern Italy. Clin Vaccine Immunol 2012; 19:1292 - 5; http://dx.doi.org/10.1128/CVI.00054-12; PMID: 22739695
   PubMed Web of Science ®Google Scholar
• Patti AM. [From the goal of the global polio eradication to the recent epidemics: reflections on the present epidemiological situation and future perspectives]. Ann Ig 2010; 22:521 - 37; PMID: 21425649
   PubMedGoogle Scholar
• Käyhty H, Peltola H, Karanko V, Mäkelä PH. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis 1983; 147:1100; http://dx.doi.org/10.1093/infdis/147.6.1100; PMID: 6602191
   PubMed Web of Science ®Google Scholar
• Kalies H, Grote V, Siedler A, Gröndahl B, Schmitt H-J, von Kries R. Effectiveness of hexavalent vaccines against invasive Haemophilus influenzae type b disease: Germany’s experience after 5 years of licensure. Vaccine 2008; 26:2545 - 52; http://dx.doi.org/10.1016/j.vaccine.2008.03.001; PMID: 18403069
   PubMed Web of Science ®Google Scholar
• Hallander HO, Lepp T, Ljungman M, Netterlid E, Andersson M. Do we need a booster of Hib vaccine after primary vaccination? A study on anti-Hib seroprevalence in Sweden 5 and 15 years after the introduction of universal Hib vaccination related to notifications of invasive disease. APMIS 2010; 118:878 - 87; http://dx.doi.org/10.1111/j.1600-0463.2010.02674.x; PMID: 20955461
   PubMed Web of Science ®Google Scholar
• Cerquetti M. Haemophilus influenzae in epoca post-vaccinale. Rome: Workshop MIB; 2012. Available from: http://www.epicentro.iss.it/problemi/meningiti/wkshpdancona/web_Cerquetti_workshop_MIB_2012.pdf
   Google Scholar
• Giufrè M, Cardines R, Caporali MG, Accogli M, D’Ancona F, Cerquetti M. Ten years of Hib vaccination in Italy: prevalence of non-encapsulated Haemophilus influenzae among invasive isolates and the possible impact on antibiotic resistance. Vaccine 2011; 29:3857 - 62; http://dx.doi.org/10.1016/j.vaccine.2011.03.059; PMID: 21459175
   PubMed Web of Science ®Google Scholar
• Kuhnert R, Schlaud M, Poethko-Müller C, Vennemann M, Fleming P, Blair PS, Mitchell E, Thompson J, Hecker H. Reanalyses of case-control studies examining the temporal association between sudden infant death syndrome and vaccination. Vaccine 2012; 30:2349 - 56; http://dx.doi.org/10.1016/j.vaccine.2012.01.043; PMID: 22289512
   PubMed Web of Science ®Google Scholar
• von Kries R, Toschke AM, Strassburger K, Kundi M, Kalies H, Nennstiel U, Jorch G, Rosenbauer J, Giani G. Sudden and unexpected deaths after the administration of hexavalent vaccines (diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, Haemophilius influenzae type b): is there a signal?. Eur J Pediatr 2005; 164:61 - 9; http://dx.doi.org/10.1007/s00431-004-1594-7; PMID: 15602672
   PubMed Web of Science ®Google Scholar
• von Kries R. Comment on B. Zinka et al., Unexplained cases of sudden infant death shortly after hexavalent vaccination. Vaccine 2006; 24:5783 - 4, author reply 5785-6; http://dx.doi.org/10.1016/j.vaccine.2005.03.055; PMID: 16081190
   PubMed Web of Science ®Google Scholar
• Traversa G, Spila-Alegiani S, Bianchi C, Ciofi degli Atti M, Frova L, Massari M, Raschetti R, Salmaso S, Scalia Tomba G, Hera Study Group. Sudden unexpected deaths and vaccinations during the first two years of life in Italy: a case series study. PLoS One 2011; 6:e16363; http://dx.doi.org/10.1371/journal.pone.0016363; PMID: 21298113
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. EMEA updatwe on hexavalent vaccines: Hexavac and Infanrix hexa. EMEA/CPMP/5889/03. London: 2003. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Public_statement/2010/01/WC500059303.pdf
   Google Scholar
• Omeñaca F, Garcia-Sicilia J, García-Corbeira P, Boceta R, Romero A, Lopez G, Dal-Ré R. Response of preterm newborns to immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B virus-inactivated polio and Haemophilus influenzae type b vaccine: first experiences and solutions to a serious and sensitive issue. Pediatrics 2005; 116:1292 - 8; http://dx.doi.org/10.1542/peds.2004-2336; PMID: 16322149
   PubMed Web of Science ®Google Scholar
• Omeñaca F, Garcia-Sicilia J, García-Corbeira P, Boceta R, Torres V. Antipolyribosyl ribitol phosphate response of premature infants to primary and booster vaccination with a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio virus/Haemophilus influenzae type b vaccine. Pediatrics 2007; 119:e179 - 85; http://dx.doi.org/10.1542/peds.2005-2907; PMID: 17145903
   PubMed Web of Science ®Google Scholar
• Omeñaca F, Garcia-Sicilia J, Boceta R, García-Corbeira P. Hepatitis B response of premature infants after primary and booster immunisation with a diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus/haemophilus influenzae type B vaccine. Infect Dis Obstet Gynecol 2010; 2010:802503; http://dx.doi.org/10.1155/2010/802503; PMID: 20396673
   PubMedGoogle Scholar
• Omeñaca F, Garcia-Sicilia J, Boceta R, Sistiaga-Hernando A, García-Corbeira P. Antibody persistence and booster vaccination during the second and fifth years of life in a cohort of children who were born prematurely. Pediatr Infect Dis J 2007; 26:824 - 9; http://dx.doi.org/10.1097/INF.0b013e318124a9c8; PMID: 17721379
   PubMed Web of Science ®Google Scholar
• Vesikari T, Wysocki J, Chevallier B, Karvonen A, Czajka H, Arsène J-P, Lommel P, Dieussaert I, Schuerman L. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine. Pediatr Infect Dis J 2009; 28:Suppl S66 - 76; http://dx.doi.org/10.1097/INF.0b013e318199f8ef; PMID: 19325449
   PubMed Web of Science ®Google Scholar
• Vesikari T, Karvonen A, Prymula R, Schuster V, Tejedor JC, Thollot F, Garcia-Corbeira P, Damaso S, Han HH, Bouckenooghe A. Immunogenicity and safety of the human rotavirus vaccine Rotarix co-administered with routine infant vaccines following the vaccination schedules in Europe. Vaccine 2010; 28:5272 - 9; http://dx.doi.org/10.1016/j.vaccine.2010.05.057; PMID: 20538094
   PubMed Web of Science ®Google Scholar
• Tejedor JC, Omeñaca F, García-Sicilia J, Verdaguer J, Van Esso D, Esporrín C, Molina V, Muro M, Marés J, Enrubia M, et al, Spanish DTPa-HBV-IPV/Hib-076 Study Group. Immunogenicity and reactogenicity of a three-dose primary vaccination course with a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-haemophilus influenzae type b vaccine coadministered with a meningococcal C conjugate vaccine. Pediatr Infect Dis J 2004; 23:1109 - 15; PMID: 15626947
   PubMed Web of Science ®Google Scholar
• Tejedor JC, Moro M, Ruiz-Contreras J, Castro J, Gómez-Campderá JA, Navarro ML, Merino JM, Martín-Ancel A, Roca J, García-del-Río M, et al, Spanish DTaP-HBV-IPV-097 Study Group. Immunogenicity and reactogenicity of primary immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type B vaccine coadministered with two doses of a meningococcal C-tetanus toxoid conjugate vaccine. Pediatr Infect Dis J 2006; 25:713 - 20; http://dx.doi.org/10.1097/01.inf.0000227725.61495.c4; PMID: 16874171
   PubMed Web of Science ®Google Scholar
• Knuf M, Pantazi-Chatzikonstantinou A, Pfletschinger U, Tichmann-Schumann I, Maurer H, Maurer L, Fischbach T, Zinke H, Pankow-Culot H, Papaevangelou V, et al. An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus toxoid conjugate vaccine co-administered with Infanrix™ hexa is immunogenic, with an acceptable safety profile in 12-23-month-old children. Vaccine 2011; 29:4264 - 73; http://dx.doi.org/10.1016/j.vaccine.2011.03.009; PMID: 21420417
   PubMed Web of Science ®Google Scholar
• Zepp F, Behre U, Kindler K, Laakmann K-H, Pankow-Culot H, Mannhardt-Laakmann W, Beckers F, Descamps D, Willems P. Immunogenicity and safety of a tetravalent measles-mumps-rubella-varicella vaccine co-administered with a booster dose of a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine in healthy children aged 12-23 months. Eur J Pediatr 2007; 166:857 - 64; http://dx.doi.org/10.1007/s00431-007-0506-z; PMID: 17541639
   PubMed Web of Science ®Google Scholar
• National Center for Immunization and Respiratory Diseases. General recommendations on immunization --- recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60:1 - 64; PMID: 21293327
   PubMedGoogle Scholar